Prevention of Oral Mucositis in Patients undergoing Chemotherapy
Autor(a) principal: | |
---|---|
Data de Publicação: | 2018 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/77 |
Resumo: | Introduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain. There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. |
id |
INCA-1_76b46d27c5a6b4a6aa2d8efcf60738db |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/77 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Prevention of Oral Mucositis in Patients undergoing ChemotherapyPrevención de la Mucositis Oral en Pacientes sometidos a la QuimioterapiaPrevenção da Mucosite Oral em Pacientes submetidos à QuimioterapiaMucositePrevenção & ControleClorexidinaMalvaMucositisPrevention & controlChlorhexidineMalvaMucositisPrevención & controlClorhexidinaMalvaIntroduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain. There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. Introducción: La quimioterapia es una forma de tratamiento de cáncer y se utilizan drogas como el 5-fluorouracilo (5-FU), mayor causante de la mucositis oral. Aún no hay un protocolo específico para la prevención de esta complicación. Objetivo: Evaluar el grado de mucositis oral durante los 10 días después de cada ciclo de quimioterapia según la auto-percepción de cada paciente y el nivel de dolor relatado con el uso de las dos sustancias estudio: té de malva y clorexidina 0,12%. Método: Los pacientes fueron aleatorizados por sorteo para la realización de enjuague con 10ml de la sustancia determinada, 3 veces al día, durante el período de infusión de la quimioterapia. En cada ciclo se utilizó una de las sustancias. Durante los 10 días después de la quimioterapia los pacientes respondieron a un cuestionario con preguntas cerradas sobre su dolor y la autopercepción de su mucosa oral. Resultados: En los ciclos utilizando el té de malva la auto-percepción del paciente pareció ser mejor, con su mucositis oral siendo de grado 1 y 2. En los ciclos utilizando clorexidina 0,12% los pacientes presentaron menos dolor. Conclusión: Tanto en los ciclos en que se utilizó la clorexidina 0,12% como en aquellos donde se utilizó el té de malva, la mayoría de los pacientes refirió presentar mucositis oral. Sin embargo, cuando se utilizó el té de malva la frecuencia de mucositis fue en menores grados. La clorexidina 0,12% pareció presentar menos sintomatología dolorosa, a pesar de la diferencia comparando las dos sustancias haber sido pequeña. Introdução: A quimioterapia é uma das formas de tratar o câncer, na qual utilizam-se drogas como o 5-fluorouracil (5-FU), maior causador da mucosite oral. Essa complicação é a causa mais comum de dor. Objetivo: Avaliar o grau de mucosite oral durante os dez dias após cada ciclo de quimioterapia, segundo a autopercepção de cada paciente e o nível de dor relatada com o uso das duas substâncias estudo: chá de malva e clorexidina 0,12%. Método: Os pacientes foram randomizados por sorteio para a realização de bochechos com 10 ml da substância determinada, três vezes ao dia, durante o período de infusão da quimioterapia. Em cada ciclo, utilizou-se uma das substâncias. Durante os dez dias após a quimioterapia, os pacientes responderam a um questionário com perguntas fechadas sobre a sua dor e a autopercepção da sua mucosa oral. Resultados: Nos ciclos utilizando o chá de malva, a autopercepção do paciente pareceu ser melhor, com sua mucosite oral sendo de graus 1 e 2. Contudo, nos ciclos utilizando clorexidina 0,12%, os pacientes apresentaram menos dor. Conclusão: Tanto nos ciclos em que foi utilizado a clorexidina 0,12% quanto naqueles onde foi utilizado o chá de malva, a maioria dos pacientes referiu apresentar mucosite oral. Porém, quando utilizado o chá de malva, a frequência de mucosite foi em menores graus. A clorexidina 0,12% pareceu apresentar menos sintomatologia dolorosa, apesar da diferença, comparando as duas substâncias, ter sido pequena.INCA2018-06-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/7710.32635/2176-9745.RBC.2018v64n2.77Revista Brasileira de Cancerologia; Vol. 64 No. 2 (2018): Apr./May/June; 189-194Revista Brasileira de Cancerologia; Vol. 64 Núm. 2 (2018): abr./mayo/jun.; 189-194Revista Brasileira de Cancerologia; v. 64 n. 2 (2018): abr./maio/jun.; 189-1942176-974510.32635/2176-9745.RBC.2018v64n2reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/77/37https://rbc.inca.gov.br/index.php/revista/article/view/77/153Valduga, FrancielliOltramari, ElenusaLemes, Letícia Tainá de OliveiraMattos, Carlos Eduardo deStefenon, LetíciaMozzini, Carolina Barretoinfo:eu-repo/semantics/openAccess2021-11-29T20:06:43Zoai:rbc.inca.gov.br:article/77Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:06:43Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy Prevención de la Mucositis Oral en Pacientes sometidos a la Quimioterapia Prevenção da Mucosite Oral em Pacientes submetidos à Quimioterapia |
title |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
spellingShingle |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy Valduga, Francielli Mucosite Prevenção & Controle Clorexidina Malva Mucositis Prevention & control Chlorhexidine Malva Mucositis Prevención & control Clorhexidina Malva |
title_short |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
title_full |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
title_fullStr |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
title_full_unstemmed |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
title_sort |
Prevention of Oral Mucositis in Patients undergoing Chemotherapy |
author |
Valduga, Francielli |
author_facet |
Valduga, Francielli Oltramari, Elenusa Lemes, Letícia Tainá de Oliveira Mattos, Carlos Eduardo de Stefenon, Letícia Mozzini, Carolina Barreto |
author_role |
author |
author2 |
Oltramari, Elenusa Lemes, Letícia Tainá de Oliveira Mattos, Carlos Eduardo de Stefenon, Letícia Mozzini, Carolina Barreto |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Valduga, Francielli Oltramari, Elenusa Lemes, Letícia Tainá de Oliveira Mattos, Carlos Eduardo de Stefenon, Letícia Mozzini, Carolina Barreto |
dc.subject.por.fl_str_mv |
Mucosite Prevenção & Controle Clorexidina Malva Mucositis Prevention & control Chlorhexidine Malva Mucositis Prevención & control Clorhexidina Malva |
topic |
Mucosite Prevenção & Controle Clorexidina Malva Mucositis Prevention & control Chlorhexidine Malva Mucositis Prevención & control Clorhexidina Malva |
description |
Introduction: The chemotherapy is one of the cancer possible treatments and use chemotherapeutic drugs as 5-fluorouracil (5-FU), major cause of oral mucositis. This complication is the most common cause of pain. There is still no specific protocol for the prevention of this complication, but there are substances used empirically and palliative. Objective: Assessing the degree of mucositis during the 10 days after each chemotherapy cycle using the self-perception of each patient and the pain level reported with the use of the two substances studied: mallow tea and 0,12% chlorhexidine. Method: The selected patients were randomly randomized to perform mouthwash with 10 ml of the test substance, 3 times a day, during the infusion time of chemotherapy. In each accompanied cycle one of the studied substances were used. During the 10 days after chemotherapy, patients answered a questionnaire with closed questions about their pain and self-perception of their oral mucosa. Results: in cycles where mallow tea was used, selfperception of patients seems to be better with your oral mucositis is grade 1 and 2. However, in cycles where 0,12% chlorhexidine was used, patients experienced less pain. Conclusion: In both cycles that was used at 0.12% chlorhexidine was used as those where the mauve tea, most of the patients reported oral mucositis present. However, when used mauve tea was obtained mucositis in minor degrees. The 0.12% chlorhexidine it appeared to have less pain symptoms, although the difference was small when compared to the two substances. |
publishDate |
2018 |
dc.date.none.fl_str_mv |
2018-06-29 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos, Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/77 10.32635/2176-9745.RBC.2018v64n2.77 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/77 |
identifier_str_mv |
10.32635/2176-9745.RBC.2018v64n2.77 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/77/37 https://rbc.inca.gov.br/index.php/revista/article/view/77/153 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 64 No. 2 (2018): Apr./May/June; 189-194 Revista Brasileira de Cancerologia; Vol. 64 Núm. 2 (2018): abr./mayo/jun.; 189-194 Revista Brasileira de Cancerologia; v. 64 n. 2 (2018): abr./maio/jun.; 189-194 2176-9745 10.32635/2176-9745.RBC.2018v64n2 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042242172485632 |